FMP
Akero Therapeutics, Inc.
AKRO
NASDAQ
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. It also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.
29.34 USD
0.94 (3.2%)
Historical Prices
From:
To:
We are unable to load the chart at this time.
About
ceo
Dr. Andrew Cheng M.D., Ph.D.
sector
Healthcare
industry
Biotechnology
website
https://www.akerotx.comexchange
NASDAQ
Description
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. It also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, I...
CIK
0001744659
ISIN
US00973Y1082
CUSIP
00973Y108
Address
601 Gateway Boulevard
Phone
650 487 6488
Country
US
Employee
60
IPO Date
Jun 20, 2019
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
AKRO Financial Summary
CIK
0001744659
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
00973Y108
ISIN
US00973Y1082
Country
US
Price
29.34
Beta
-0.26
Volume Avg.
574.4k
Market Cap
2.05B
Shares
-
52-Week
15.32-37.0
DCF
3.95
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-7.76
P/B
-
Website
https://www.akerotx.com
Upgrades and Downgrades
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest AKRO News
It looks like there's no news available.
